Jyoti Nangalia

Dr. Jyoti Nangalia is a Principal Investigator at the Wellcome-MRC Cambridge Stem Cell Institute and a Cancer Research UK Clinician Scientist at the Wellcome Sanger Institute. She holds a dual affiliation with the Department of Haematology at the University of Cambridge. Dr. Nangalia is also a Consultant Haematologist specializing in myeloproliferative neoplasms (MPN). Her research focuses on somatic mutagenesis, clonal evolution in blood cancers, and the integration of genomic data into clinical practice.

Education: MBBS (Medicine) from the University of Cambridge, followed by a PhD at the Cambridge Institute of Medical Research, where she discovered CALR mutations in JAK2-unmutated MPNs. This discovery has become a standard diagnostic criterion in clinical practice.

Research Interests: Her lab explores clonal trajectories in blood cancers, methylation dynamics across human lifespan, and personalized cancer prognosis modeling. Recent work includes tracing the evolutionary history of MPNs over decades, revealing disease origins decades before clinical presentation.

Grants & Funding: Supported by CRUK, Rosetrees Trust, Alborada Trust, and MPN Research Foundation. Her group collaborates with clinical teams to inform early intervention strategies and refine diagnostic tools.

• Labs/Teams: The Nangalia Group operates at both the Stem Cell Institute and Sanger Institute, focusing on translational research in haematological malignancies.
• Advising: Supervises postgraduate students (e.g., Aleksandra Kamizela, Sreeya Kodavali) and mentors visiting researchers in genomic analysis and clonal evolution studies.